A Case of Diffuse Infiltrative Hepatocellular Carcinoma with Marked Response to Sorafenib Treatment Evidenced by <sup>18</sup>F-FDG PET/MRI
PDF
Cite
Share
Request
Interesting Image
P: 0-0

A Case of Diffuse Infiltrative Hepatocellular Carcinoma with Marked Response to Sorafenib Treatment Evidenced by 18F-FDG PET/MRI

Mol Imaging Radionucl Ther 0;0(0):0-0
1. Ankara University Faculty of Medicine, Department of Nuclear Medicine, Ankara, Türkiye
2. Ankara University Faculty of Medicine, Department of Radiology, Ankara, Türkiye
3. Ankara University Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology, Ankara, Türkiye
No information available.
No information available
Received Date: 26.01.2024
Accepted Date: 03.03.2024
PDF
Cite
Share
Request

ABSTRACT

A 73-year-old woman with known diagnosis of chronic hepatitis B infection referred for 18F-fluorodeoxyglucose positron emission tomography/ computed tomography (18F-FDG PET/CT) and magnetic resonance imaging (MRI) after detection of a liver mass with 9 cm diameter in contrast enhanced CT. However, 18F-FDG PET/CT and MRI revealed diffuse infiltrating hepatocellular carcinoma lesions other than previously defined mass. After 9 months of Sorafenib treatment serum alpha feto protein levels dropped from 60,500 ng/mL to 801 ng/mL. Later 18F-FDG PET/MRI was performed for evaluation of response to treatment and revealed marked response to treatment.

Keywords: Hepatocellular carcinoma, positron emission tomography, fluorodeoxyglucose, magnetic resonance imaging, sorafenib

References

2024 ©️ Galenos Publishing House